Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT06071429
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 300 participants
- Sponsor
- R3 Vascular Inc.
- Registry
-
NCT06071429
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06071429. Randomized; single masking; primary purpose treatment. Start 2025-04-11 (actual); primary completion 2028-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease
- Acronym
- ELITE-BTK
- Condition
- Chronic Limb-Threatening Ischemia
- Intervention (Device)
- MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold
- Intervention (Device)
- Percutaneous Transluminal Angioplasty (PTA)
- Lead sponsor
- R3 Vascular Inc.
Record details
- Record id
cardio:ct-nct06071429- Content hash
7d434534aced34d39f8b12bac601da1b21a7216e85254d1570d56b1cf6797405